Stockscreener 앱 받기
42.48
1.26%
0.53
전일 마감가:
$41.95
열려 있는:
$41.95
하루 거래량:
1.15M
Relative Volume:
0.65
시가총액:
$2.28B
수익:
-
순이익/손실:
$-38.99M
주가수익비율:
-14.18
EPS:
-2.9966
순현금흐름:
$-24.94M
1주 성능:
-1.21%
1개월 성능:
-14.18%
6개월 성능:
-50.33%
1년 성능:
-7.63%
1일 변동 폭
$41.34
$43.70
1주일 범위
$39.43
$45.45
52주 변동 폭
$39.43
$90.32
Soleno Therapeutics Inc Stock (SLNO) Company Profile
명칭
Soleno Therapeutics Inc
전화
650-213-8444
주소
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
SLNO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SLNO
Soleno Therapeutics Inc
|
42.48 | 2.25B | 0 | -38.99M | -24.94M | -2.9966 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-18 | 개시 | Wolfe Research | Outperform |
| 2025-10-07 | 개시 | Goldman | Buy |
| 2025-08-20 | 개시 | Wells Fargo | Overweight |
| 2025-06-23 | 개시 | TD Cowen | Buy |
| 2025-03-05 | 재개 | Stifel | Buy |
| 2024-12-02 | 재확인 | Robert W. Baird | Outperform |
| 2024-12-02 | 재확인 | Stifel | Buy |
| 2024-09-03 | 개시 | H.C. Wainwright | Buy |
| 2024-05-10 | 개시 | Robert W. Baird | Outperform |
| 2024-02-05 | 개시 | Piper Sandler | Overweight |
| 2024-01-23 | 개시 | Stifel | Buy |
| 2023-11-21 | 재개 | Guggenheim | Buy |
| 2020-09-29 | 개시 | Guggenheim | Buy |
| 2020-01-10 | 개시 | Craig Hallum | Buy |
| 2019-12-23 | 개시 | Oppenheimer | Outperform |
| 2018-02-13 | 재확인 | Maxim Group | Buy |
모두보기
Soleno Therapeutics Inc 주식(SLNO)의 최신 뉴스
Momentum Shift: What is Soleno Therapeutics Incs revenue forecast2025 Year in Review & Consistent Growth Equity Picks - baoquankhu1.vn
Market Outlook: Is Soleno Therapeutics Inc forming a breakout patternJuly 2025 Momentum & Long Hold Capital Preservation Plans - baoquankhu1.vn
Soleno Therapeutics (SLNO) Faces Investor Scrutiny Amid - GlobeNewswire
Soleno Therapeutics (SLNO) Faces Investor Scrutiny Amid Disappointing VYKAT XR Starts, Discontinuations; Shares Down 26% -- Hagens Berman - GlobeNewswire Inc.
Soleno Therapeutics (SLNO) may find a bottom soon, here's why you should buy the stock now - MSN
Dow Update: Is Monogram Technologies Inc trading at a discountWeekly Stock Summary & Precise Entry and Exit Recommendations - baoquankhu1.vn
Q4 EPS Estimate for Soleno Therapeutics Increased by Analyst - MarketBeat
Soleno Therapeutics (SLNO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Finviz
Soleno Therapeutics: Why I’m Staying On The Sidelines (NASDAQ:SLNO) - Seeking Alpha
Jobs Data: Is Soleno Therapeutics Inc in a bullish channel2025 Earnings Impact & Trade Opportunity Analysis - baoquankhu1.vn
Relative Strength Alert For Soleno Therapeutics - Nasdaq
Cantor Fitzgerald reiterates Overweight rating on Soleno Therapeutics stock By Investing.com - Investing.com Nigeria
Cantor Fitzgerald reiterates Overweight rating on Soleno Therapeutics stock - Investing.com
A Look At Soleno Therapeutics (SLNO) Valuation After Profitable Q4 2025 And VYKAT XR Adoption - Sahm
Baird lowers Soleno Therapeutics stock price target to $107 on new starts trajectory - Investing.com Nigeria
Wall Street Recap: Will Soleno Therapeutics Inc. stock see insider buyingWeekly Investment Summary & Reliable Breakout Forecasts - Bộ Nội Vụ
Soleno Therapeutics (NASDAQ:SLNO) Hits New 1-Year LowTime to Sell? - MarketBeat
Soleno Therapeutics stock hits 52-week low at 41.47 USD By Investing.com - Investing.com Nigeria
Soleno reports $189-191 million in 2025 VYKAT XR sales since launch - Investing.com Nigeria
SLNO Investors: Contact Kirby McInerney LLP About Investigation into Soleno Therapeutics, Inc. - marketscreener.com
Soleno Therapeutics (NASDAQ:SLNO) Shares Gap UpTime to Buy? - MarketBeat
Soleno Therapeutics stock falls despite revenue beat as patient starts decline - Investing.com UK
Rally Mode: Will Soleno Therapeutics Inc stock deliver shareholder valueWeekly Investment Report & Technical Entry and Exit Tips - Bộ Nội Vụ
Soleno Therapeutics stock hits 52-week low at 41.47 USD - Investing.com
Soleno Therapeutics up on forecasting preliminary 2025 Vykat XR sales above estimates - TradingView — Track All Markets
Soleno Therapeutics, Inc. (SLNO) Stock Analysis: A Potential Upside of 164% Captures Investor Attention - DirectorsTalk Interviews
Soleno Therapeutics Announces Select Preliminary Fourth Quarter and Full-Year 2025 Results - The Manila Times
Market Review: Why Soleno Therapeutics Inc stock is popular among millennialsWeekly Profit Report & Long-Term Capital Growth Strategies - moha.gov.vn
Peregrine Capital Management LLC Makes New Investment in Soleno Therapeutics, Inc. $SLNO - MarketBeat
Soleno Therapeutics, Inc.Common Stock (NQ: SLNO - FinancialContent
Soleno Therapeutics (SLNO) among stocks that will bounce back according to analysts - MSN
SLNO Investigation: Investors Encouraged to Contact Kirby McInerney LLP - Bluefield Daily Telegraph
Soleno Therapeutics (NASDAQ:SLNO) Trading Down 4.2%What's Next? - MarketBeat
Why Soleno Therapeutics stock is down today: investor alerts revive Vykat XR scrutiny - TechStock²
Will Peer‑Reviewed VYKAT XR Data Calm Safety Debate And Change Soleno Therapeutics' (SLNO) Narrative? - Sahm
Soleno Therapeutics (SLNO) Among Stocks That Will Bounce Back According to Analysts - Insider Monkey
Why Soleno Therapeutics Inc. stock is popular among millennialsWeekly Investment Report & Safe Entry Momentum Stock Tips - ulpravda.ru
Assessing Soleno Therapeutics (SLNO) Valuation After JCEM VYKAT XR Data And FDA Approval - Yahoo Finance
Macro Review: Can Soleno Therapeutics Inc. stock hit record highs againJuly 2025 Short Interest & Expert Curated Trade Setups - ulpravda.ru
Can Soleno Therapeutics Inc. stock hit record highs again2025 Major Catalysts & Smart Investment Allocation Tips - ulpravda.ru
Bragar Eagel & Squire, P.C. Encourages Soleno, Avita, and Coty Investors to Contact the ... - Bluefield Daily Telegraph
Bragar Eagel & Squire, P.C. Encourages Soleno, Avita, and - GlobeNewswire
12 Stocks that Will Bounce Back According to Wall Street Analysts - Insider Monkey
Will Soleno Therapeutics Inc. stock deliver strong dividend growthQuarterly Profit Review & Expert Curated Trade Setup Alerts - ulpravda.ru
What technical signals suggest for Soleno Therapeutics Inc. stockOil Prices & Weekly Setup with ROI Potential - ulpravda.ru
Does Soleno Therapeutics Inc. stock trade at a discount to peersWeekly Stock Report & Weekly High Return Opportunities - ulpravda.ru
Soleno Therapeutics announces entry into $100M accelerated share repurchase agreement - MSN
Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics - Yahoo Finance
Soleno Therapeutics (SLNO) Receives a Buy from Wells Fargo - The Globe and Mail
Is Soleno Therapeutics Inc. stock supported by strong fundamentalsEconomic Data Impact & Market-Leading Growth Rates - ulpravda.ru
Soleno Therapeutics (NASDAQ:SLNO) Upgraded by Zacks Research to "Strong-Buy" Rating - MarketBeat
Soleno Therapeutics Inc (SLNO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):